Harmony Biosciences Holdings (HRMY) Fair Value & Analysis
Healthcare · US · Market cap $2.1B
Harmony Biosciences Holdings
HRMY · US
Fair value as of: Jul 12, 2026
From 26 valuation models · updated 10 days ago
Share price +10.7% over the past month.
Price vs Fair Value (12 months)
12‑month range $25.90 – $40.51 · fair‑value band $45.23 – $123.91 · the $36.84 price screens below the $60.30 fair value. As of Jul 12, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Harmony Biosciences Holdings (HRMY) currently trades at $36.84, while our model-based Fair Value estimate is $60.30, implying the stock looks roughly 63.7% undervalued today. We read business quality at 66/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Harmony Biosciences Holdings generated revenue of $899M at a net margin of 16.2%. Revenue grew 16.6% year over year. It earns a return on equity of 17.9%. The balance sheet holds a net cash position of $513M. Fundamentals as of Jul 12, 2026
Our scenario range runs from $45.23 (bear case) to $123.91 (bull case); at $36.84, the current price sits below that range. The share trades about 10% below its 52-week high and 44% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -28% fair-value upside, at 64%, HRMY screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 12, 2026. TTM = trailing twelve months.
About the company
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Harmony Biosciences Holdings reported revenue of $868M in FY2025 versus $305M in FY2021, a compound +29.9%/yr. Reported net income was $159M in FY2025, compounding +46.3%/yr from FY2021.
Is HRMY fairly valued? → Check now
Recent news
- Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026
- HRMY Posts Preliminary Q2 Revenues, Announces CFO Transition
- Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transiti
- Wall Street Analysts See a 27.35% Upside in Harmony Biosciences (HRMY): Can the Stock Really Move This High?
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection, not financial advice.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 449.62 MXN | -94% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$54.63 | R$46.79 | -14% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
| CSL Limited CSL | A$97.91 | A$100.60 | +3% |
| Celltrion, Inc 068270 | 160,500 KRW | 76,943 KRW | -52% |
| BioNTech SE B1NT34 | R$27.80 | R$23.67 | -15% |
| WuXi Biologics (Cayman) Inc 2269 | HK$30.74 | HK$28.99 | -6% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
| Genmab A/S GMAB | kr 1,656 | kr 524.15 | -68% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Harmony Biosciences Holdings (HRMY) undervalued?
What is the fair value of HRMY?
What is the quality score of HRMY?
What is the revenue of Harmony Biosciences Holdings (HRMY)?
What is the net profit margin of HRMY?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Harmony Biosciences Holdings analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.